I still find it remarkable that between Feb and June of 2013 RVX was trading between roughly $2.90 and $3.56 prior to the ASSURE phase 2b trial results and now, with all of the remarkable post hoc findings and some of the best scientists in the world over seeing this phase 3 trial nearing top line findings, hopefully in Q4 2018, that the stock is trading in the $2.00 to $2.40 range and the stock is being shorted. It is traded roughly at a buck less than the spring 2013 price.

The various theories have been discussed at length. The fact that the big boys are in and not bailing is certainly positive. The fact that the big boys other than Hepalink did not jump in to carry the trial through still has me scratching my head on both the science and the business sides and there has not been a mention on this issue from Don.

I certainly feel like GAC and others that the stock is tightly held. From my perspective I'm holding shares in a compound that could be a blockbuster, breakthrough molecule. More importantly the underlying theory of BET inhibition could lead to entirely new approaches in disease treatments and RVX seems to have a lead on the intellectual side of this game regarding CVD.

We'll know soon, whether tomorrow re a DSMB report or a SSRA or we'll hear at the top lines. Either way, both are soon in this rather long journey.

GLTA

Toinv